Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2806-2813

  Zhang, Tianyu ^a   Bishai, William R ^a,b   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; ISONIAZID; LINEZOLID; MOXIFLOXACIN; RESERPINE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; PHOTOPROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; CONTROLLED STUDY; GENETIC ENGINEERING; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; VIBRIO HARVEYI; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; LUMINESCENT PROTEINS; MICROBIAL SENSITIVITY TESTS; MODELS, GENETIC; MYCOBACTERIUM ULCERANS; RESERPINE; TETRACYCLINE;

EID: 77953775139     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00400-10     Document Type: Article

References (54)

1. Amaral, L., M. Martins, and M. Viveiros. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59:1237-1246.
2. Andini, N., and K. A. Nash. 2006. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob. Agents Chemother. 50:2560-2562.
3. Andrew, P. W., and I. S. Roberts. 1993. Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents. J. Clin. Microbiol. 31:2251-2254.
4. Arain, T. M., A. E. Resconi, M. J. Hickey, and C. K. Stover. 1996. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob. Agents Chemother. 40:1536-1541.
5. Arain, T. M., A. E. Resconi, D. C. Singh, and C. K. Stover. 1996. Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Antimicrob. Agents Chemother. 40:1542-1544.
6. Barker, L. P., S. F. Porcella, R. G. Wyatt, and P. L. Small. 1999. The Mycobacterium marinum G13 promoter is a strong sigma 70-like promoter that is expressed in Escherichia coli and mycobacteria species. FEMS Microbiol. Lett. 175:79-85.
7. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
8. Bourn, W. R., Y. Jansen, H. Stutz, R. M. Warren, A. L. Williamson, and P. D. van Helden. 2007. Creation and characterisation of a high-copy-number version of the pAL5000 mycobacterial replicon. Tuberculosis (Edinb.) 87:481-488.
9. Buriánková, K., F. Doucet-Populaire, O. Dorson, A. Gondran, J. C. Ghnassia, J. Weiser, and J. L. Pernodet. 2004. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48:143-150.
10. Chauty, A., M. F. Ardant, A. Adeye, H. Euverte, A. Guèdè enon, C. Johnson, J. Aubry, E. Nuermberger, and J. Grosset. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035.
11. Choudhuri, B. S., S. Bhakta, R. Barik, J. Basu, M. Kundu, and P. Chakrabarti. 2002. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem. J. 367:279-285.
12. Cooksey, R. C., J. T. Crawford, W. R. Jacobs, Jr., and T. M. Shinnick. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1348-1352.
13. Dossou, A. D., G. E. Sopoh, C. R. Johnson, Y. T. Barogui, D. Affolabi, S. Y. Anagonou, T. Zohoun, F. Portaels, and K. Asiedu. 2008. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin. Med. J. Aust. 189:532-533.
14. Durfee, T., R. Nelson, S. Baldwin, G. Plunkett III, V. Burland, B. Mau, J. F. Petrosino, X. Qin, D. M. Muzny, M. Ayele, R. A. Gibbs, B. Csörgo, G. Pósfai, G. M. Weinstock, and F. R. Blattner. 2008. The complete genome sequence of Escherichia coli DH10B: insights into the biology of a laboratory work-horse. J. Bacteriol. 190:2597-2606.
15. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
16. Faber, W. R., L. M. Arias-Bouda, J. E. Zeegelaar, A. H. Kolk, P. A. Fonteyne, J. Toonstra, and F. Portaels. 2000. First reported case of Mycobacterium ulcerans infection in a patient from China. Trans. R. Soc. Trop. Med. Hyg. 94:277-279.
17. Galluzzi, L., and M. Karp. 2006. Whole cell strategies based on lux genes for high throughput applications toward new antimicrobials. Comb. Chem. High Throughput Screen. 9:501-514.
18. Gavigan, J. A., J. A. Aínsa, E. Pérez, I. Otal, and C. Martín. 1997. Isolation by genetic labeling of a new mycobacterial plasmid, pJAZ38, from Mycobacterium fortuitum. J. Bacteriol. 179:4115-4122.
19. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854-857.
20. González-Flecha, B., and B. Demple. 1994. Intracellular generation of superoxide as a by-product of Vibrio harveyi luciferase expressed in Escherichia coli. J. Bacteriol. 176:2293-2299. (Pubitemid 24118178)
21. Hanahan, D. 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166:557-580.
22. Hickey, M. J., T. M. Arain, R. M. Shawar, D. J. Humble, M. H. Langhorne, J. N. Morgenroth, and C. K. Stover. 1996. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob. Agents Chemother. 40:400-407.
23. Howard, N. S., J. E. Gomez, C. Ko, and W. R. Bishai. 1995. Color selection with a hygromycin-resistance-based Escherichia coli-mycobacterial shuttle vector. Gene 166:181-182.
24. Ji, B., S. Lefrançois, J. Robert, A. Chauffour, C. Truffot, and V. Jarlier. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50:1921-1926.
25. Lee, M. H., L. Pascopella, W. R. Jacobs, Jr., and G. F. Hatfull. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc. Natl. Acad. Sci. U. S. A. 88:3111-3115.
26. Li, X. Z., and H. Nikaido. 2009. Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555-1623.
27. Manabe, Y. C., C. L. Hatem, A. K. Kesavan, J. Durack, and J. R. Murphy. 2005. Both Corynebacterium diphtheriae DtxR(E175K) and Mycobacterium tuberculosis IdeR(D177K) are dominant positive repressors of IdeR-regulated genes in M. tuberculosis. Infect. Immun. 73:5988-5994.
28. Marsollier, L., N. Honoré, P. Legras, A. L. Manceau, H. Kouakou, B. Carbonnelle, and S. T. Cole. 2003. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47:1228-1232.
29. Reference deleted.
30. Nienhuis, W. A., Y. Stienstra, W. A. Thompson, P. C. Awuah, K. M. Abass, W. Tuah, N. Y. Awua-Boateng, E. O. Ampadu, V. Siegmund, J. P. Schouten, O. Adjei, G. Bretzel, and T. S. van der Werf. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672.
31. Pasca, M. R., P. Guglierame, F. Arcesi, M. Bellinzoni, E. De Rossi, and G. Riccardi. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178.
32. Pedulla, M. L., M. H. Lee, D. C. Lever, and G. F. Hatfull. 1996. A novel host factor for integration of mycobacteriophage L5. Proc. Natl. Acad. Sci. U. S. A. 93:15411-15416.
33. Peña, C. E., J. E. Stoner, and G. F. Hatfull. 1996. Positions of strand exchange in mycobacteriophage L5 integration and characterization of the attB site. J. Bacteriol. 178:5533-5536.
34. Picardeau, M., C. Le Dantec, and V. Vincent. 2000. Analysis of the internal replication region of a mycobacterial linear plasmid. Microbiology 146:305-313. (Pubitemid 30099205)
35. Piddock, L. J., K. J. Williams, and V. Ricci. 2000. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45:159-165.
36. Portaels, F., H. Traore, K. De Ridder, and W. M. Meyers. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
37. Portaels, F., M. T. Silva, and W. M. Meyers. 2009. Buruli ulcer. Clin. Dermatol. 27:291-305.
38. Ramón-García, S., C. Martín, J. A. Aínsa, and E. De Rossi. 2006. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 57:252-259.
39. Roberts, E. A., A. Clark, and R. L. Friedman. 2005. Bacterial luciferase is naturally destabilized in Mycobacterium tuberculosis and can be used to monitor changes in gene expression. FEMS. Microbiol. Lett. 243:243-249.
40. Rubin, E. J., B. J. Akerley, V. N. Novik, D. J. Lampe, R. N. Husson, and J. J. Mekalanos. 1999. In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 96:1645-1650.
41. Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. Jacobs, Jr. 1990. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 4:1911-1919.
42. Snewin, V. A., M. P. Gares, P. O. Gaora, Z. Hasan, I. N. Brown, and D. B. Young. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593.
43. Stinear, T., B. C. Ross, J. K. Davies, L. Marino, R. M. Robins-Browne, F. Oppedisano, A. Sievers, and P. D. Johnson. 1999. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J. Clin. Microbiol. 37:1018-1023.
44. Stinear, T. P., A. Mve-Obiang, P. L. Small, W. Frigui, M. J. Pryor, R. Brosch, G. A. Jenkin, P. D. Johnson, J. K. Davies, R. E. Lee, S. Adusumilli, T. Garnier, S. F. Haydock, P. F. Leadlay, and S. T. Cole. 2004. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc. Natl. Acad. Sci. U. S. A. 101:1345-1349.
45. Stinear, T. P., H. Hong, W. Frigui, M. J. Pryor, R. Brosch, T. Garnier, P. F. Leadlay, and S. T. Cole. 2005. Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J. Bacteriol. 187:1668-1676.
46. Stinear, T. P., M. J. Pryor, J. L. Porter, and S. T. Cole. 2005. Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology 151:683-692.
47. Stinear, T. P., T. Seemann, S. Pidot, W. Frigui, G. Reysset, T. Garnier, G. Meurice, D. Simon, C. Bouchier, L. Ma, M. Tichit, J. L. Porter, J. Ryan, P. D. Johnson, J. K. Davies, G. A. Jenkin, P. L. Small, L. M. Jones, F. Tekaia, F. Laval, M. Daffé, J. Parkhill, and S. T. Cole. 2007. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome. Res. 17:192-200.
48. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, W. R. Jacobs, Jr., and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460.
49. Tullius, M. V., G. Harth, and M. A. Horwitz. 2001. High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism. Infect. Immun. 69:6348-6363.
50. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
51. Wansbrough-Jones, M., and R. Phillips. 2006. Buruli ulcer: emerging from obscurity. Lancet 367:1849-1858.
52. Wards, B. J., and D. M. Collins. 1996. Electroporation at elevated temperatures substantially improves transformation efficiency of slow-growing mycobacteria. FEMS Microbiol. Lett. 145:101-105.
53. Williamson, H. R., M. E. Benbow, K. D. Nguyen, D. C. Beachboard, R. K. Kimbirauskas, M. D. McIntosh, C. Quaye, E. O. Ampadu, D. Boakye, R. W. Merritt, and P. L. Small. 2008. Distribution of Mycobacterium ulcerans in Buruli ulcer endemic and non-endemic aquatic sites in Ghana. PLoS Negl. Trop. Dis. 2:e205.
54. Zhang, Y., R. Lathigra, T. Garbe, D. Catty, and D. Young. 1991. Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis. Mol. Microbiol. 5:381-391.